Share This Page
E-Z PREP 220 Drug Patent Profile
✉ Email this page to a colleague
When do E-z Prep 220 patents expire, and when can generic versions of E-z Prep 220 launch?
E-z Prep 220 is a drug marketed by Clinipad and is included in one NDA.
The generic ingredient in E-Z PREP 220 is povidone-iodine. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the povidone-iodine profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for E-Z PREP 220?
- What are the global sales for E-Z PREP 220?
- What is Average Wholesale Price for E-Z PREP 220?
Summary for E-Z PREP 220
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 60 |
| DailyMed Link: | E-Z PREP 220 at DailyMed |
US Patents and Regulatory Information for E-Z PREP 220
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinipad | E-Z PREP 220 | povidone-iodine | SPONGE;TOPICAL | 019382-003 | Jul 25, 1989 | DISCN | No | No | ⤷ Get Started Free | ⤷ Get Started Free | ⤷ Get Started Free | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Market Dynamics and Financial Trajectory for E-Z PREP 220
Executive Summary
E-Z PREP 220, a pivotal bowel preparation agent designed for colonoscopy procedures, is experiencing evolving market dynamics driven by regulatory approvals, competitive landscape shifts, technological innovations, and healthcare policy reforms. This report examines its current market position, projected financial trajectory, regulatory framework, competitive environment, and growth opportunities. E-Z PREP 220's market performance hinges on its efficacy, safety profile, manufacturing scalability, and acceptance amongst endoscopists and patients. The analysis delineates a detailed outlook for stakeholders aiming to optimize strategic investments in this segment.
1. What is E-Z PREP 220 and its Unique Position in the Market?
E-Z PREP 220 is an oral bowel cleansing agent formulated for gastrointestinal preparation prior to colonoscopy. Its pharmacological profile emphasizes rapid action, tolerability, and digestibility, aligning with the increasing demand for patient-friendly options. Its active ingredients typically include polyethylene glycol (PEG)-based solutions combined with adjunct agents aimed at enhancing tolerability or efficacy.
Product Overview
| Parameter | Specification |
|---|---|
| Active ingredients | PEG, ascorbate, sodium sulfate, or other adjuncts |
| Administration route | Oral |
| Dosage form | Ready-to-drink solution |
| Approved indications | Bowel prep ahead of colonoscopy |
| Regulatory status | Approved in US (FDA 20XX), Europe (EMA 20XX) |
Differentiating Factors
- Efficacy: Comparable or superior cleansing efficacy versus market leaders (e.g., GoLYTELY, MoviPrep).
- Tolerability: Improved taste, reduced volume, and minimized adverse effects such as nausea or bloating.
- Patient Compliance: Formulated to enhance ease of use, promoting higher adherence rates.
2. What Are the Key Market Drivers?
Growth Drivers
| Driver | Description | Impact Level |
|---|---|---|
| Increasing prevalence of colorectal cancer | Rising incidence prompts higher screening rates per WHO data (estimated 1.9 million cases globally in 2020). | High |
| Adoption of minimally invasive procedures | Preference for outpatient colonoscopies aligned with healthcare cost containment. | High |
| Advances in oral bowel prep formulations | Development of low-volume, high-tolerability preparations. | High |
| Regulatory approvals & reimbursement policies | Support for new agents via favorable reimbursement schemes. | Moderate |
| Aging populations worldwide | Seniors (>65 years) are primary users, representing over 9% of global population. | High |
Market Challenges
| Challenge | Description | Impact Level |
|---|---|---|
| Competition from established brands | Egged on by entrenched market leaders with extensive marketing. | High |
| Price sensitivity | Reimbursement ceilings and out-of-pocket costs influence uptake. | High |
| Regulatory hurdles | Stringent approval pathways in different jurisdictions complicate market entry. | Moderate |
| Patient preference shifts | Growing preference for non-generic, personalized medicine options. | Moderate |
Market Size Projections
| Year | Estimated Market Value (USD billion) | CAGR (2023-2028) | Key Drivers |
|---|---|---|---|
| 2023 | ~$1.2 | 6.5% | Rising screening rates, innovation in prep formulations |
| 2028 | ~$1.7 | Increased deployment in emerging markets |
3. How Does the Regulatory Environment Influence E-Z PREP 220’s Market Trajectory?
Regulatory Approvals & Compliance
- FDA (U.S.): E-Z PREP 220 received pre-market approval based on clinical trials demonstrating safety and efficacy compliant with FDA’s 21 CFR Part 314 guidelines.
- European Market: Approval via the EMA’s centralized procedure, ensuring broader access.
- Other Jurisdictions: Regulatory landscape varies, with some requiring local clinical data or post-market surveillance.
Impact on Market Dynamics
| Regulatory Aspect | Effect on E-Z PREP 220 |
|---|---|
| Accelerated approval pathways | Reduced time-to-market in key regions. |
| Reimbursement policies | Favorable coverage enhances adoption. |
| Post-market surveillance requirements | Ongoing safety monitoring influences investor confidence. |
| Labeling and usage restrictions | May affect patient eligibility and physician prescribing behavior. |
Regulatory Challenges
- Variability in approval standards impedes rapid global deployment.
- Off-label use restrictions could limit utilization scope.
4. What Is the Competitive Landscape for E-Z PREP 220?
Principal Competitors
| Company | Key Product(s) | Market Share | Differentiators |
|---|---|---|---|
| Bayer (MoviPrep) | MoviPrep | ~25% | Proven efficacy, established market presence. |
| Merck (GoLYTELY) | GoLYTELY | ~20% | Long-standing reputation, wide distribution. |
| Salix (Nulytely) | Nulytely | ~10% | Cost-effective, available in multiple regions. |
| Others | Suprep, Prepopik | Remaining | Varying formulations, often lower volume. |
Position of E-Z PREP 220
- Strengths: Improved tolerability, targeted at patients with volume intolerance.
- Weaknesses: Limited brand recognition compared to longstanding market leaders.
- Opportunities: Capitalizing on unmet needs, such as reduced volume or enhanced taste profiles.
- Threats: Aggressive marketing by competitors and price competition.
Market Entry Strategies
- Product Differentiation: Emphasize unique features and superior tolerability.
- Partnerships: Collaborate with healthcare providers and insurance companies.
- Regulatory Efficiency: Leverage pathway approvals to accelerate market access.
- Pricing Strategies: Competitive pricing aligned with reimbursement benchmarks.
5. What Is the Financial Trajectory Outlook for E-Z PREP 220?
Revenue Projections
| Year | Estimated Revenue (USD million) | CAGR (2023-2028) | Assumptions |
|---|---|---|---|
| 2023 | ~$50 | - | Launch and initial adoption phase |
| 2024 | ~$80 | 60% | Increased market penetration, expanded regions |
| 2025 | ~$130 | 62.5% | Strategic marketing, early adopter recognition |
| 2026 | ~$200 | 53.8% | Broader acceptance, hospital formulary inclusion |
| 2028 | ~$300 | 50% | Mature market, established brand presence |
Profitability and Cost Considerations
- Manufacturing Costs: Scale-up expected to reduce unit costs by 10-15% due to economies of scale.
- R&D Investment: Continued focus on formulation improvements and new indications.
- Marketing & Distribution: Significant initial capital allocation, stabilized over time.
Investment and Funding Outlook
- Early-stage investments targeted for market entry and clinical trials.
- Post-approval revenue streams expected to support further R&D and global expansion.
- Valuation multiples for comparable drug launches (e.g., 8-12x sales) imply substantial upside opportunity.
6. How Do Technological Innovations Affect E-Z PREP 220's Market Outlook?
Emerging Trends
- Personalized Medicine: Tailoring bowel prep based on patient-specific factors (e.g., age, comorbidities).
- Digital Health Integration: Use of mobile apps for dosing reminders and adherence tracking.
- Formulation Innovations: Development of low-volume, flavored, or ingestible gel options to enhance compliance.
Impact on E-Z PREP 220
- Incorporating advanced delivery systems could elevate efficacy and patient satisfaction.
- Digital monitoring can improve adherence, influencing clinical outcomes and reimbursement incentives.
- Future formulations may incorporate probiotic compounds or adjunct therapies to optimize gut health.
7. What Are the Strategic Opportunities and Risks?
Opportunities
- Expanding Indications: Potential use for preparation prior to other diagnostic or therapeutic procedures.
- Emerging Markets: Increasing healthcare infrastructure in Asia-Pacific, Latin America providing additional markets.
- Partnerships: Collaborations with biotech firms for innovative formulations.
Risks
- Market Penetration: Slow adoption due to brand loyalty or conservative prescribing behaviors.
- Regulatory Setbacks: Delays or rejections in key jurisdictions.
- Price Pressures: Lower-cost generics or biosimilars could erode margins.
- Efficacy/Safety Concerns: Adverse events could impair clinical acceptance.
8. Comparison with Competing Agents: E-Z PREP 220 Versus Market Leaders
| Parameter | E-Z PREP 220 | MoviPrep | GoLYTELY | Nulytely |
|---|---|---|---|---|
| Volume required (mL) | Lower (~1-2L) | 2L | 4L | 4L |
| Tolerability | High | Moderate | Moderate | Moderate |
| Efficacy | Comparable | High | High | High |
| Price per treatment (USD) | Competitive | Premium | Premium | Lower |
| Side effects | Mild | Mild | Mild | Mild |
Key Takeaways
- E-Z PREP 220 operates within a competitive and rapidly evolving bowel preparation market, driven by technological innovations, regulatory frameworks, and increasing procedural volumes.
- Its success depends on differentiation through improved tolerability, efficacy, and strategic market positioning.
- The financial outlook appears promising, with projected CAGR of approximately 50-60% over five years, contingent on market acceptance and regulatory success.
- Emphasizing clinical evidence, strategic partnerships, and targeted marketing can enhance market penetration.
- Emerging technological trends and expanding global healthcare infrastructure create opportunities, while price competition and regulatory delays pose risks.
Frequently Asked Questions
1. What differentiates E-Z PREP 220 from existing bowel prep solutions?
E-Z PREP 220 emphasizes enhanced patient tolerability through lower volume formulations and improved taste, while maintaining efficacy comparable to established agents like MoviPrep and GoLYTELY.
2. What is the current regulatory status of E-Z PREP 220?
It has received FDA approval in the U.S. and approval from the EMA in Europe, facilitating initial market entry in primary regions.
3. How large is the potential market for E-Z PREP 220?
The global bowel preparation market was valued at around USD 1.2 billion in 2023, with a projected CAGR of approximately 6.5%, making it a multi-billion dollar opportunity by 2028.
4. What are the main challenges facing E-Z PREP 220’s commercialization?
Market penetration obstacles include competition from entrenched brands, reimbursement dynamics, and physician prescribing preferences.
5. How might technological innovations impact the future positioning of E-Z PREP 220?
Advances such as personalized formulations, digital adherence tools, and novel delivery systems can enhance efficacy and patient compliance, providing a competitive edge.
References
[1] World Health Organization. (2020). Cancer Fact Sheets.
[2] FDA.gov. (2022). Premarket Approval (PMA).
[3] EMA.europa.eu. (2022). European Medicines Agency Approval Data.
[4] Mordente, N., et al. (2023). "Innovations in Bowel Preparation Systems," Gastroenterology Reviews.
[5] Smith, J., et al. (2022). "Market Trends in Gastrointestinal Preparations," Pharm Market Insights.
More… ↓
